Foghorn Therapeutics (FHTX) Price & Analysis

Compare

403 Followers

FHTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.94 - $10.25

Previous CloseN/A

Volume24.60K

Average Volume (3M)107.93K

Market Cap

$225.75M

Enterprise Value$213.51M

Total Cash (Recent Filing)$220.59M

Total Debt (Recent Filing)$34.85M

Price to Earnings (P/E)―

Beta2.06

Next Earnings

Aug 12, 2025

EPS Estimate

-0.35

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.30

Shares Outstanding55,741,370

10 Day Avg. Volume88,969

30 Day Avg. Volume107,934

Financial Highlights & Ratios

PEG Ratio-0.19

Price to Book (P/B)-4.38

Price to Sales (P/S)0.00

P/FCF Ratio-2.50

Enterprise Value/Market Cap0.95

Enterprise Value/Revenue2.00

Enterprise Value/Gross Profit9.08

Enterprise Value/Ebitda-0.56

Forecast

1Y Price Target

$10.67

Price Target Upside163.46% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Foghorn Therapeutics News

PremiumThe Fly

Foghorn Therapeutics reports Q1 EPS (30c), consensus (29c)

15d ago

FHTX

PremiumThe Fly

Foghorn Therapeutics sees cash runway into 2027

15d ago

FHTX

PremiumThe Fly

Foghorn Therapeutics appoints Neil Gallagher, Stuart Duty to board

28d ago

FHTX

PremiumCompany Announcements

Foghorn Therapeutics Reports Q1 2025 Financial Results

15d ago

FHTX

PremiumRatings

Promising Advancements and Strategic Collaborations Drive Buy Rating for Foghorn Therapeutics

15d ago

FHTX

PremiumRatings

Foghorn Therapeutics: Pioneering Precision Medicine with Innovative Pharmacology and AI Integration

15d ago

FHTX

PremiumCompany Announcements

Foghorn Therapeutics Advances FHD-909 Phase 1 Trial

15d ago

FHTX

PremiumPre-Earnings

Is FHTX a Buy, Before Earnings?

19d ago

FHTX

See All FHTX News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical AdvancementsPreclinical data presented at AACR 2025 showcased robust tumor regression across multiple SMARCA4-mutant NSCLC models.

Pharmaceutical InnovationTargeted protein degradation and induced proximity are rapidly reshaping the therapeutic landscape, and may represent the next inflection point in precision medicine.

Strategic CollaborationsFoghorn continues to progress its strategic collaboration with Lilly for FHD-909, which has been the main focus of investor interest in the company.

Bears Say

Financial PerformanceFoghorn reported Q1 collaboration revenues of $6M, below the $10M estimate.

Revenue ConcernsFoghorn reported Q4 collaboration revenue of $3M below the $10M estimate.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

1.32% Insiders

9.71% Mutual Funds

45.60% Other Institutional Investors

38.11% Public Companies and Individual Investors

Detailed Ownership Overview >

FHTX FAQ

What was Foghorn Therapeutics, Inc.’s price range in the past 12 months?

Foghorn Therapeutics, Inc. lowest stock price was $2.94 and its highest was $10.25 in the past 12 months.

What is Foghorn Therapeutics, Inc.’s market cap?

Foghorn Therapeutics, Inc.’s market cap is $225.75M.

When is Foghorn Therapeutics, Inc.’s upcoming earnings report date?

Foghorn Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2025 which is in 75 days.

How were Foghorn Therapeutics, Inc.’s earnings last quarter?

Foghorn Therapeutics, Inc. released its earnings results on May 14, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.309 by $0.009.

Is Foghorn Therapeutics, Inc. overvalued?

According to Wall Street analysts Foghorn Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Foghorn Therapeutics, Inc. pay dividends?

Foghorn Therapeutics, Inc. does not currently pay dividends.

What is Foghorn Therapeutics, Inc.’s EPS estimate?

Foghorn Therapeutics, Inc.’s EPS estimate is -0.35.

How many shares outstanding does Foghorn Therapeutics, Inc. have?

Foghorn Therapeutics, Inc. has 55,741,370 shares outstanding.

What happened to Foghorn Therapeutics, Inc.’s price movement after its last earnings report?

Foghorn Therapeutics, Inc. reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.309. Following the earnings report the stock price went down -5.081%.

Which hedge fund is a major shareholder of Foghorn Therapeutics, Inc.?

Currently, no hedge funds are holding shares in FHTX

Foghorn Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

322.49%

Trailing 12-Months

Asset Growth

1.45%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Foghorn Therapeutics, Inc.

Foghorn Therapeutics (FHTX) is a biotechnology company focused on discovering and developing a new class of medicines targeting chromatin regulatory proteins. By leveraging their proprietary Gene Traffic Control platform, Foghorn Therapeutics aims to treat a wide range of diseases, including cancer. The company is based in the United States and operates within the healthcare and biotechnology sectors.

FHTX Stock 12 Month Forecast

Average Price Target

$10.67

▲(163.46%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","14":"$14"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5,8,11,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Sep<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.16,4.84,5.52,6.2,6.88,7.56,8.24,8.92,9.6,10.28,10.959999999999999,11.64,12.32,{"y":13,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.16,4.6607692307692306,5.161538461538462,5.662307692307692,6.163076923076924,6.663846153846154,7.164615384615384,7.665384615384616,8.166153846153847,8.666923076923077,9.167692307692308,9.668461538461539,10.169230769230769,{"y":10.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.16,4.532307692307692,4.904615384615385,5.276923076923077,5.649230769230769,6.021538461538461,6.3938461538461535,6.766153846153847,7.138461538461538,7.510769230769231,7.883076923076922,8.255384615384616,8.627692307692307,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.68,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.13,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.86,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.51,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.28,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.03,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.72,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >